title: 11-Keto-β-Boswellic Acids Prevent Development of Autoimmune Reactions, Insulitis and Reduce Hyperglycemia During Induction of Multiple Low-Dose Streptozotocin (MLD-STZ) Diabetes in Mice.
abstract: The aim of the work was to study whether or not 11-keto-β-boswellic acids prevent induction of autoimmune reactions, insulitis, and hyperglycemia in the model of multiple low-dose streptozotocin (MLD-STZ) diabetes. Using male mice (n = 6) diabetes was induced by daily i.p. injections of 40 mg/kg STZ for 5 days. In a second series together with STZ, daily i. p. injections of 11-keto-β-boswellic acid (KBA) and O-acetyl-11-keto-β-boswellic acid (AKBA) (7.5 and 15.0 mg/kg) were applied for 10 days. Thereafter, pro-and anti-inflammatory cytokines in the blood, histochemistry of pancreatic islets, and blood glucose levels were assayed. Five days after the last injection of STZ, a significant burst of pro-and anti-inflammatory cytokines in the blood, infiltration of lymphocytes (CD3) into pancreatic islets, and appearance of peri-insular apoptotic cells were observed. Plasma glucose increased significantly (124.4 ± 6.65 vs. 240.2 ± 27.36 mg/dl, p <0.05). Simultaneous treatment with KBA and AKBA significantly reduced pro-and anti-inflammatory cytokines (IFN-γ p < 0.01, p < 0.01; IL-1A p < 0.001, p < 0.001; IL-1B p < 0.001, p < 0.001; IL-2 p < 0.001, p < 0.001; IL-6 p < 0.01, p < 0.001; TNF-α p < 0.05, p < 0.001; IL-4 p < 0.01, p < 0.001; IL-10 p < 0.001, p < 0.001) in the blood. No infiltration of lymphocytes into pancreatic islets and appearance of peri-insular cells were detected. Moreover, KBA and AKBA reduced STZ-mediated increase of blood glucose on day 10 to 163.25 ± 16.6 (p < 0.05) and 187.6 ± 19.5 mg/dl (p < 0.05), respectively. In the model of MLD-STZ induced diabetes KBA and AKBA prevent cytokine burst, development of insulitis and reduce increase of blood glucose through "silencing" a forced-up immune reaction.
authors.affiliation: Department of Pharmacology, Institute of Pharmaceutical Sciences, University of Tübingen, Tübingen, Germany.
authors.forename: A M
authors.initials: AM
authors.lastname: Shehata
authors.affiliation: Institute of Pathology, University of Tübingen, Tübingen, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Quintanilla-Fend
authors.affiliation: Institute of Pathology, University of Tübingen, Tübingen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Bettio
authors.affiliation: Institute of Pharmaceutical Sciences, University of Saarland, Saarbrücken, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Jauch
authors.affiliation: Department of Pharmacy, Faculty of Chemical Sciences, BUAP, Mexico.
authors.forename: T
authors.initials: T
authors.lastname: Scior
authors.affiliation: Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.
authors.forename: W A
authors.initials: WA
authors.lastname: Scherbaum
authors.affiliation: Department of Pharmacology, Institute of Pharmaceutical Sciences, University of Tübingen, Tübingen, Germany.
authors.forename: H P T
authors.initials: HP
authors.lastname: Ammon
mesh_terms: D000818:Animals; D015551:Autoimmunity / Q000187:drug effects* / Q000276:immunology; D001786:Blood Glucose; D016207:Cytokines / Q000097:blood*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000276:immunology; D006943:Hyperglycemia / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D007328:Insulin / Q000097:blood; D007515:Islets of Langerhans / Q000187:drug effects / Q000276:immunology; D008297:Male; D051379:Mice; D014315:Triterpenes / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: C447943:11-keto-boswellic acid; D001786:Blood Glucose; D016207:Cytokines; D007328:Insulin; D014315:Triterpenes; C094432:acetyl-11-ketoboswellic acid